Introduction and Objectives Long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) are first-line treatments for COPD. The addition of inhaled corticosteroids (ICS) is recommended for patients with frequent exacerbations who are not adequately controlled with long-acting bronchodilators. These medications have been largely evaluated independently in placebo controlled randomised trials. In this ‘real-life’ study we investigated the impact of these medications used independently and in combination on mortality.
Methods We conducted a retrospective cohort study using data from patients with a diagnosis of COPD in NHS Tayside between 2001 and 2010. All-cause and cardiovascular mortality was assessed using Cox proportional hazard regression after adjustment for FEV1, age, sex, smoking pack-years, oxygen saturation, cardiovascular and respiratory admissions; cardiovascular medications and diabetes. Patients on short-acting bronchodilators only were used as the controls.
Results A total of 5048 patients were included in the study with mean age at diagnosis of 69.4 years and mean follow-up of 4.0 years. 623 were on long-acting bronchodilators only, 3510 on long-acting bronchodilator and ICS; and 915 controls. Crude hazard ratios are shown in Table 1. Adjusted HR (95%CI) for all-cause mortality for LABA only, LAMA only; and LABA + LAMA were 0.70 (0.45–1.09), 0.52 (0.37–0.73) and 0.53 (0.34–0.84) respectively. Adjusted HR for all-cause mortality for LABA + ICS, LAMA + ICS; LABA + LAMA + ICS were 0.56 (0.45 – 0.70), 0.34 (0.25 – 0.47) and 0.29 (0.24 – 0.36) respectively. Adjusted HR for cardiovascular mortality for LABA only, LAMA only; and LABA + LAMA were 0.63 (0.28–1.44), 0.41 (0.21 – 0.79) and 0.39 (0.17 – 0.90) respectively, and for LABA + ICS, LAMA + ICS; LABA + LAMA + ICS were 0.50 (0.33 – 0.75), 0.23 (0.12 – 0.45) and 0.22 (0.15 – 0.33) respectively.
Conclusions LABA monotherapy does not confer any mortality benefit but when used in combination with ICS reduces both all-cause and cardiovascular mortality. In contrast, LAMA whether given alone or in combination with a LABA and /or ICS reduces both all-cause and cardiovascular mortality. This ‘real-life’ study suggests that LABA should perhaps not be given as monotherapy but only in conjunction with a LAMA or ICS.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.